The 6th iPSC Drug Development Summit convenes senior biopharma leaders working to advance induced pluripotent stem cell therapies into the clinic and toward commercial readiness. Held September 9–10 in Boston, the meeting is dedicated exclusively to iPSC based drug development, with focused discussion spanning translational science, CMC strategy, GMP ready manufacturing, and regulatory alignment. The agenda is shaped around active programs and real development decisions, with presentations from organizations including Astellas Pharma, BlueRock Therapeutics, Aspen Neuroscience, Century Therapeutics, Vertex Pharmaceuticals, and Broadoak Capital. 

Designed for R&D, clinical, and technical decision makers, the summit provides practical insight into platform selection, scalability, quality control, and risk management. Structured networking connects developers, investors, and solution providers navigating shared scientific and operational challenges across the evolving iPSC landscape.